Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ipsen buys rare disease company Clementia for over $1bn cash plus CVRs

Executive Summary

Ipsen will acquire rare disease drug developer Clementia Pharmaceuticals Inc. for up to $1.3bn, or $1.04bn in cash ($25 per share in cash, a 43% discount) and $6 per share in contingent value rights (CVRs).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies